Evidence map›Paper›PMID 41234234›Full record

ArticleFrontiers in endocrinology2025

Luyao Zhang, Yanpeng Xing, Pai Wang, Jianlei Gu, Jian Peng, Juan Huang, James Alexander Pearson, Youjia Hu, Hongyu Zhao, F Susan Wong and 1 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luyao Zhang *Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Yanpeng Xing *Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Pai WangDepartment of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Jianlei GuDepartment of Biostatiscs & Data Science, Yale School of Public Health, New Haven, CT, United States.
Jian PengSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Juan HuangSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
James Alexander PearsonDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Youjia HuSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Hongyu ZhaoDepartment of Biostatiscs & Data Science, Yale School of Public Health, New Haven, CT, United States.
F Susan WongDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Li WenSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pancreatic β-cell dysfunction is a key contributor to the development of Type 2 Diabetes. The platelet-derived growth factor receptor α (PDGFRα) is known to play a crucial role in β-cell proliferation and expansion. However, its specific role in β-cell function and glucose metabolism remains unclear. This study aimed to investigate the effects of Pdgfrα deficiency on islet β-cell function and overall glucose metabolism. Methods: To explore this, we generated β-cell-specific Pdgfrα-deficient C57BL/6 mice (Pdgfra Results: Pdgfrα-deficient mice exhibited significantly greater weight gain and increased body fat compared to controls. These mice also showed impaired glucose metabolism, reduced insulin content in β-cells, and increased β-cell apoptosis. Mechanistic studies revealed that Pdgfrα deletion led to suppression of Atf5 expression via downregulation of the PI3K pathway. This suppression resulted in enhanced β-cell apoptosis. Furthermore, Atf5 was found to regulate the expression of Gadd45b, Bcl2, and aminoacyl-tRNA synthetases, which are involved in insulin biosynthesis and glucose metabolism. Discussion: Our findings demonstrate that PDGFRα plays a critical role in maintaining β-cell function and glucose homeostasis. Loss of PDGFRα impairs β-cell survival and insulin production, likely through the PI3K-Atf5 axis. These insights suggest that targeting β-cell apoptotic pathways, particularly involving Atf5 and its downstream effectors, may offer promising avenues for the prevention and treatment of Type 2 Diabetes.

Indexed as

ApoptosisGlucoseInsulin-Secreting CellsReceptor, Platelet-Derived Growth Factor alphaAnimalsDiabetes Mellitus, Type 2Diet, High-FatInsulinMaleMiceMice, Inbred C57BLMice, KnockoutSignal TransductionUp-RegulationGlucoseInsulinReceptor, Platelet-Derived Growth Factor alphaapoptosisATF5Gadd45bobesitypancreatic beta cellsPDGFR alpha

Identifiers

PMID41234234
PMCPMC12605365

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.